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Although the histological changes seen in psoriasis
have long been well characterized, the underlying
cellular and molecular mechanisms have only begun
to be elucidated over the past 20 years. Proinflamma-
tory factors such as tumor necrosis factor (TNF)-a have
a central role in psoriasis pathogenesis, and many
T-helper 1 (Th1) cytokines and messenger RNAs are
elevated in psoriatic lesions. IL-17A, IL-17F, and other
Th17 cell–derived cytokines have been shown in
murine models to induce features that mimic human
psoriasis. This review focuses on the emerging
biology of the IL-17 cytokine family in psoriasis, and
on the molecular and genetic information gained
from animal models and human clinical studies that
confirm IL-17 as a crucial proinflammatory cytokine in
psoriasis. Expression of IL-17A, IL-17C, and IL-17F is
strikingly increased in psoriatic lesions, and success-
ful therapy is associated with restoration of the
expression of a wide range of genes (including
effector molecules downstream of IL-17 such as
cytokines, chemokines, and antimicrobial peptides)
to near-normal levels. Therapeutic agents in develop-
ment that target IL-17 are discussed, and an emerging
model of the key role of IL-17 in the pathogenesis of
psoriasis is presented.
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INTRODUCTION
Psoriasis is a chronic debilitating disease, affecting 1–2% of
the Caucasian population (Naldi, 2004; Gudjonsson and
Elder, 2007) and characterized by recurrent episodes of red
and scaly well-demarcated skin plaques (Schon and
Boehncke, 2005). The histological changes observed within
lesional skin include (1) a thickened epidermis from rapid
keratinocyte proliferation and aberrant differentiation, (2) a
reduced or absent granular layer, (3) marked dilatation of
blood vessels in the papillary dermis, and (4) dense clusters of
inflammatory cells composed of T cells and dendritic cells in
the dermis, and CD8þ T cells and neutrophils in the
epidermis (Schon and Boehncke, 2005). Histological ab-
normalities in psoriasis have been well described for decades
and include multiple elements that indicate immune-
mediated inflammation. However, the cellular and molecular
mechanisms underlying the pathophysiological changes have
only recently been brought into sharp focus by studies
describing global alterations in the psoriasis lesional tran-
scriptome, as well as the impressive success of targeted
therapeutics in the clinic.
Our understanding of the role of various immune cells and
inflammatory factors involved in psoriasis pathogenesis has
progressed over the past 20 years. Early clinical studies, such
as those with calcineurin inhibitors (Ellis et al., 1986; Griffiths
et al., 1986) and agents targeting IL-2 receptor–expressing cells
(Gottlieb et al., 1995), have demonstrated the integral role of
the immune system, and specifically T cells, in psoriasis
pathogenesis (Ghoreschi et al., 2007). The central role
of proinflammatory factors in the development of psoriasis
was demonstrated by the success of therapeutic agents that
target tumor necrosis factor (TNF)-a in the treatment of
psoriasis (Chaudhari et al., 2001; Leonardi et al., 2003). TNF-
a, a proinflammatory factor, is secreted by activated T cells
and dendritic cells. The T-helper 1 (Th1) subset of activated T
cells is the numerically dominant T-cell subset in psoriatic
lesions (Kryczek et al., 2008; Lowes et al., 2008) and has been
the focus of much attention in psoriasis since the mid 1980s.
Many recognized Th1 cytokines and messenger RNAs
(mRNAs), including IFN-g and TNF-a, are elevated in psoriatic
skin lesions (Austin et al., 1999; Lowes et al., 2008).
Development of Th1 cells is driven by IL-12, and a recent
therapeutic agent targeting IL-12 through the shared IL-12/
23p40 subunit, has also shown strong efficacy (Leonardi et al.,
2008). However, more recently, the focus has shifted toward a
novel subset of T cells expressing IL-17: Th17 cells, which are
also elevated in psoriatic lesions (Lowes et al., 2008; Res
et al., 2010). Development of Th17 cells is driven by IL-23
and therefore, similar to Th1 cells, would be reduced by
inhibition of the IL-12/23p40 shared subunit. Results from
multiple rodent models of autoimmunity have led to a
significant paradigm shift, with Th17 cells and IL-17 replacing
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the Th1 cells and associated cytokines as dominant mediators
of tissue damage (Harrington et al., 2005; Langrish et al.,
2005; Park et al., 2005; Steinman, 2007).
Genome-wide association studies and analysis of candi-
date genomic regions have implicated components of the
IL-23 and IL-17 signaling pathways in the development of
psoriasis (Table 1), further focusing attention on Th17 cells in
this disease. This review will focus on the emerging role of
IL-17 in psoriasis, with particular emphasis on the biology of
IL-17 in the skin and the lessons learned from animal models
and human clinical studies that confirm IL-17 as a crucial
cytokine in psoriasis.
THE ROLE OF IL-17 IN IMMUNE DEFENSE AND IN
PRECLINICAL DISEASE MODELS
T-helper 17 cells are CD4þ effector T-helper cells that are
distinct from the classic Th1 and Th2 lineages. They are
defined most notably by the ability to produce large
quantities of IL-17A and are thought to have evolved to
provide both innate and adaptive immunity against patho-
gens (Gaffen, 2009). Th17 cells differentiate from naive T
cells after stimulation with transforming growth factor-b, IL-6,
IL-21, and IL-1b (Acosta-Rodriguez et al., 2007; Yang et al.,
2008). Th17 cells are subsequently activated by IL-23, IL-1b,
and IL-21 to produce multiple inflammatory factors in
addition to IL-17A, including IL-17F and IL-22, although this
latter cytokine is produced to a much greater extent in murine
Th17 cells than in human cells (Awasthi et al., 2009; Ciric
et al., 2009; Sutton et al., 2009). In humans, Th17 and a
separate type of IL-22–producing cells called Th22 cells have
been identified, but the classification of T-helper sets is not
simple. Human dermal T cells have been shown to produce
any combination of IL-17, IL-22, and IFN-g, although the
number of cells uniquely producing either IL-17 or IL-22
exceeds the number producing both (Nograles et al., 2008).
The relative production of various cytokines in individual
Th17 cells is influenced by the levels of different activating
signals, most notably from cytokines and pathogens (Zielinski
et al., 2012). In addition to Th17 cells, a subset of cytotoxic T
cells (Tc) that also produce IL-17 (Tc17) is present in psoriatic
lesions; these cells also produce Th17-related cytokines,
including IL-17A (Kryczek et al., 2008), IL-21, and IL-22
(Ortega et al., 2009).
IL-17 is part of a family of cytokines consisting of the
prototypical ligand, IL-17 (IL-17A), and five other IL-17
ligands (IL-17B through IL-17F; Figure 1; Gaffen, 2009;
Pappu et al., 2010). IL-17A and IL-17F are known to act as
homodimers or as IL-17A/F heterodimers (Chang and Dong,
2007; Wright et al., 2007). IL-17E (renamed IL-25) also
exists in a dimeric form (Rickel et al., 2008; Claudio et al.,
2009). The IL-17 receptors consist of five receptor family
members, namely, IL-17 receptor A through IL-17 receptor E.
Among the several members of the IL-17 receptor family,
IL-17 receptor A contains an extended cytoplasmic domain
with unique signaling properties (Gaffen, 2009) and has been
implicated as a heteromeric partner for other IL-17 receptors,
when binding various ligands. IL-17A and IL-17F homo-
dimers and heterodimers signal through the heteromeric
Table 1. Summary of genetic association data for IL-17–related genes involved in psoriasis
Locus Other diseases Pathways IL-17 relevance References
IL23A IL-23 Upstream Nair et al., 2009
IL12B IBD, PsA, AS, MS IL-23 Upstream Cargill et al., 2007; Fisher et al., 2008; Nair et al., 2009; Nair et al.,
2008; Parkes et al., 2007; Patsopoulos et al., 2011; Wellcome Trust
Case Control. et al., 2007; Zhang et al., 2009
IL23R IBD, PsA, AS,
Behcet
IL-23 Upstream Cargill et al., 2007; Duerr et al., 2006; Filer et al., 2008; Jiang et al.,
2010; Mizuki et al., 2010; Nair et al., 2009; Remmers et al., 2010;
Wellcome Trust Case Control et al., 2007
TYK2 IBD, SLE, MS? IL-23 Upstream Australia and New Zealand Multiple Sclerosis Genetics
Consortium, 2009; Ban et al., 2009; Franke et al., 2010; Sigurdsson
et al., 2005; Strange et al., 2010
TRAF3IP2 PsA IL-17 and
NF-kB
Downstream Ellinghaus et al., 2010; Huffmeier et al., 2009; Strange et al., 2010
REL PsA, RA, CeD NF-kB Up/downstream Ellinghaus et al., 2012; Gregersen et al., 2009; Strange et al., 2010;
Trynka et al., 2009
NFKBIA PsA NF-kB Up/downstream Strange et al., 2010; Stuart et al., 2010
TNFAIP3 PsA, SLE, RA, CeD NF-kB Up/downstream Graham et al., 2008; Musone et al., 2008; Nair et al., 2009; Plenge
et al., 2007; Strange et al., 2010; Thomson et al., 2007; Trynka
et al., 2009
TNIP1 PsA, SLE, SSc NF-kB Up/downstream Allanore et al., 2011; Gateva et al., 2009; Nair et al., 2009;
Strange et al., 2010
DEFB4 IL-17–regulated
gene
Downstream Hollox et al., 2008
Abbreviations: AS, ankylosing spondylitis; CeD, celiac disease; IBD, inflammatory bowel disease (including Crohn’s disease and ulcerative colitis);
MS, multiple sclerosis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.
18 Journal of Investigative Dermatology (2013), Volume 133
DA Martin et al.
Role of IL-17 in Psoriasis
receptor consisting of IL-17 receptor A and IL-17 receptor C
(Kuestner et al., 2007; Wright et al., 2008). IL-17E (IL-25)
signals through a heteromeric receptor containing IL-17
receptor A and IL-17 receptor B (Rickel et al., 2008; Claudio
et al., 2009). Recently, IL-17C was demonstrated to require
both IL-17 receptor E and IL-17 receptor A for signaling
(Ramirez-Carrozzi et al., 2011; Song et al., 2011). Much less
is known about IL-17B and IL-17D, but IL-17B is believed to
signal through IL-17 receptor B (Shi et al., 2000; Gaffen,
2009). It is unclear whether the receptors for IL-17B and
IL-17D are heteromeric, and whether IL-17 receptor A may
be a common co-receptor for all IL-17 family ligands.
IL-17A acts on a variety of cell types including endothelial
cells, fibroblasts, chondrocytes, synovial cells, monocytes,
and epithelial cells including keratinocytes (Yao et al., 1997;
Honorati et al., 2001; Harper et al., 2009). IL-17A and IL-17F
act directly on keratinocytes to stimulate the production of a
number of molecules known to be elevated in psoriasis
lesional tissue such as cytokines, b-defensins, and antimicro-
bial peptides (AMPs), and neutrophil-, macrophage-, and
lymphocyte-attracting chemokines such as IL-8, CCL20 (also
called macrophage inflammatory protein-3a), and CCL2 (also
called monocyte chemotactic protein 1; Guttman-Yassky
et al., 2008). IL-17C, similar to IL-17A and IL-17F, has also
recently been demonstrated to act on keratinocytes to induce
human b-defensin 2 and granulocyte colony–stimulating
factor (Ramirez-Carrozzi et al., 2011). IL-17E (IL-25) is
distinct from IL-17A, IL-17C, and IL-17F in that it is generally
produced by epithelial cells during an allergic response and
acts to induce Th2-type responses (Kleinschek et al., 2007;
Rickel et al., 2008; Barlow and McKenzie, 2009). Expression
of IL-17E (IL-25), IL-17B, and IL-17D is not increased in
lesional psoriatic skin compared with nonlesional skin
(Johansen et al., 2009); therefore, these cytokines likely do
not have a major role in the development of psoriasis.
There is evidence suggesting involvement of the IL-17
system in antimicrobial defense via the maintenance of
mucocutaneous immunity. In contrast to the low fungal
burdens in mice lacking IL-12 or IL-22, IL-17RA-deficient
mice are more susceptible to Candida albicans infections
(Huang et al., 2004; Kagami et al., 2010a), potentially due to
neutrophil and AMP defects (Conti et al., 2011; Gaffen et al.,
2011). This susceptibility is also evident in rare human
genetic diseases associated with chronic mucocutaneous
candidiasis that are linked to lack of IL-17 signaling, either
through autosomal IL17RA or IL17F mutations (Puel et al.,
2011) or high titers of neutralizing antibodies to IL-17
cytokines (e.g., autoimmune polyendocrine syndrome type
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Figure 1. IL-17 family ligands and receptors. There are six well-defined IL-17 ligands and five receptors. The IL-17A, IL-17F, and IL-17C ligands have elevated
expression in psoriatic skin and have their presumed major cellular sources in the skin highlighted, although other sources may contribute. Those three ligands,
and IL-17E (IL-25), have demonstrated heteromeric receptor complexes, which in all cases include the IL-17 receptor A subunit and one specific other IL-17
receptor subunit partner. Major cytoplasmic factors interacting with the IL-17 receptor complex are shown, as an example, for the IL-17RA/RC complex, where
they are best studied. The IL-17A and IL-17F ligands form homo- and heterodimeric complexes. A dimeric state of the other ligands is illustrated by analogy, but
has not been demonstrated, and the exact stoichiometries of the heteromeric receptor complexes are not fully determined. The ligand–receptor interactions are
less well defined for IL-17B and IL-17D, and the requirement for an IL-17 receptor A subunit is unknown. GI, gastrointestinal; IL-17R, IL-17 receptor; LTi,
lymphoid tissue inducer; Mfs, macrophages; NKT, natural killer T; Th17, T-helper 17.
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1 due to mutations in the AIRE gene; Puel et al., 2010).
Finally, in a distinct but phenotypically related genetic twist-
of-fate, most patients with hyper-IgE syndrome, who tend to
be affected by mucocutaneous candidiasis and Staphylococ-
cus aureus infections, have dominant negative mutations in
STAT3, which can lead to Th17 and IL-17 deficiency due to a
loss in the IL-6 and IL-23 signaling required for Th17 lineage
induction and stabilization (Milner et al., 2008). The degree
to which these human genetic diseases that affect either IL-
17/IL-17R or Th17 cells (and hence affect a broad number of
cytokines) are relevant to partial blockade with antagonists
specific to IL-17/IL-17R will be further informed by ongoing
clinical studies.
In addition to their potential role in mucocutaneous
immunity, Th17 cells also may be involved in vascular
inflammation, including atherosclerotic plaque responses to
Chlamydophila pneumoniae (Chen et al., 2010; Benagiano
et al., 2012). Although atheroma formation in the mouse
C. pneumoniae system can be inhibited by genetic defects of
IL-17A (Chen et al., 2010), results of biochemical blockade in
other murine systems are mixed (Taleb et al., 2009; Smith
et al., 2010). A proatherogenic role for IL-17A is supported by
the lack of atherosclerotic changes associated with coronary
artery defects in patients with hyper-IgE syndrome (Freeman
et al., 2011). Furthermore, patients with psoriasis, who are at
increased cardiovascular risk (Mehta et al., 2011), have been
reported to have increased circulating IL-17A–producing cells
(Kagami et al., 2010b; Bovenschen et al., 2011).
Expression of Th17-derived cytokines is elevated in
murine models of the skin inflammation that mimic features
of human psoriasis (van der Fits et al., 2009; Blumberg et al.,
2010; Singh et al., 2010; Nakajima et al., 2011), and
decreases in IL-17A and IL-17F are seen with successful
treatments (Blumberg et al., 2010; Singh et al., 2010).
Antibodies to IL-17A, IL-23p19, or to the shared IL-12/
23p40 subunit show efficacy in some models (Blumberg
et al., 2010; Nakajima et al., 2011). Data from mouse models
have shown that inhibition of IL-23 alone provides compar-
able efficacy to IL-12/23p40 dual inhibition (Blumberg et al.,
2010; Tonel et al., 2010; Nakajima et al., 2011; Rizzo et al.,
2011), suggesting that IL-23 is the dominant p40-containing
cytokine in psoriasis. IL-23 is known to induce IL-22 in
addition to IL-17A, and inhibition of IL-22 has been shown to
be efficacious in at least one mouse model of psoriasis (Ma
et al., 2008). Direct injection of IL-22 into mouse ears or
human skin equivalents is sufficient to induce some gene
expression changes similar to psoriasis, as well as keratino-
cyte hyperplasia and parakeratosis (Boniface et al., 2005; Sa
et al., 2007; Ma et al., 2008). It is therefore possible that
inhibition of IL-22 in addition to IL-17A would be required for
full efficacy seen with IL-23 inhibition. However, IL-17
receptor A knockout mice (which lack signaling through
multiple IL-17 family members) were shown to be as resistant
as IL-23 knockout mice in a psoriasis-like model in which
lesions are induced by imiquimod, a toll-like receptor 7/8
ligand (van der Fits et al., 2009).
We sought to address the question of differential efficacy
by comparing IL-23 and IL-17 (both ligand and receptor)
inhibition in a preclinical model of skin inflammation
(Amgen, unpublished data on file). In this model, IL-36a
(IL-36a/IL-1F6; an IL-1 ligand family member) transgenic
mice under the control of a keratinocyte (K14) promoter were
treated with the phorbol ester 12-O-tetradecanoylphorbol-
13-acetate (Blumberg et al., 2010), leading to the induction of
many pathologic features of psoriasis and induction of
cytokines and chemokines involved in psoriasis (Blumberg
et al., 2010). This model allowed direct comparison of
inhibition of IL-12/23p40, IL-23, IL-17A and IL-17F, and IL-17
receptor A. Similar to published studies, IL-12/23p40– and
IL-23–specific antagonism was highly efficacious (Blumberg
et al., 2010), whereas IL-17A–specific inhibition was only
moderately effective (Amgen, unpublished data on file).
Antagonism of IL-17F alone was similar to isotype control
antibody. Interestingly, inhibition of IL-17 receptor A pro-
vided greater benefit over IL-17A-specific inhibition and was
as efficacious as IL-23 inhibition. These data suggest that
combined inhibition of multiple IL-17 family ligands through
targeting of IL-17 receptor A may have more profound effects
in the skin than inhibition of IL-17A alone and that inhibition
of IL-22 is not necessary to achieve efficacy comparable to
IL-23 inhibition (Amgen, unpublished data on file). Further-
more, these data suggest that another IL-17 family member in
addition to IL-17A and IL-17F may be playing a role in the
skin. IL-17C has recently been demonstrated to act on
keratinocytes to induce proinflammatory cytokines, chemo-
kines, and AMPs, and this activity requires both IL-17
receptor E and IL-17 receptor A (Ramirez-Carrozzi et al.,
2011; Song et al., 2011). Finally, IL-17C knockout mice had
significantly decreased inflammation and epidermal thicken-
ing in the imiquimod psoriasis-like model (Ramirez-Carrozzi
et al., 2011), further suggesting that IL-17C, in addition to
IL-17A, could be contributing to the efficacy seen with IL-17
receptor A inhibition in the IL-36 transgenic model of psoriasis.
These data collectively suggest that inhibition of one or more
IL-17 family members has therapeutic potential for psoriasis.
BIOLOGY OF IL-17 IN HUMAN PSORIASIS
There is substantial evidence demonstrating the central
contribution of Th17 cells and, more directly, IL-17 to plaque
psoriasis in humans (Harper et al., 2009; Johansen et al.,
2009). Genome-wide association and other genetic studies
clearly have linked multiple IL-17–related genes to psoriasis
pathogenesis (Table 1). The molecular and cellular analyses
of psoriatic skin have increased our understanding of disease
pathogenesis beyond a Th1-driven disease, which was
generally accepted until relatively recently. Finally, the
remarkable and exciting results in clinical trials have
confirmed the central contribution of IL-17 to psoriasis,
including both a correlation of IL-17 pathway changes with
successful therapy as well as demonstration of the direct
effects of inhibition of both IL-17A and IL-17 receptor A.
Expression of IL-17A, IL-17C, and IL-17F is elevated in
psoriatic lesional tissue compared with nonlesional tissue
(Harper et al., 2009; Johansen et al., 2009; Russell et al.,
2011). Paired punch biopsies from lesional skin from patients
with psoriasis showed significantly higher protein levels of
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IL-17A, IL-17C, and IL-17F (6.7-fold, 4.1-fold, and 8-fold
higher, respectively) compared with nonlesional skin
(Johansen et al., 2009).
CD4þ Th17 cells are present in higher numbers in
psoriatic lesions than in healthy skin and are decreased after
treatment (Lowes et al., 2008). Immunostaining of lesional
samples from inflamed skin also showed increased numbers
of cells positive for IL-17A (Lowes et al., 2008; Harper et al.,
2009). Recent studies have suggested that many of these
IL-17–positive cells could be CD8þ T cells (Tc17), lymphoid
tissue–inducer cells, mast cells, and/or neutrophils rather than
T-helper cells (Cua and Tato, 2010; Res et al., 2010; Lin et al.,
2011). The relative contribution of these different cell types
will be important in understanding their role in psoriasis
pathogenesis.
Human genetic studies have shown that several of the risk
alleles involved in psoriasis may be risk alleles for other
autoimmune disorders (recently reviewed by Capon et al.
[2012]) and/or influence IL-17, both upstream of IL-17
expression at the IL-23 cytokine/IL-23R signaling level
(Cargill et al., 2007; Nair et al., 2008, 2009) and downstream
of the IL-17 receptor (Ellinghaus et al., 2010; Huffmeier et al.,
2010). Four of these genes are part of the IL-23/IL-23R
signaling system (Table 1; Cargill et al., 2007; Huffmeier
et al., 2009; Nair et al., 2009; Ellinghaus et al., 2010; Strange
et al., 2010): IL23A, IL12B, IL23R, and tyrosine kinase 2
(TYK2). IL23A and IL23R are specific to IL-23 signaling and
IL12B codes for the shared IL12/23p40 subunit; TYK2 is a
signaling kinase downstream of IL-12 and IL-23 (Nakamura
et al., 2008). Notably, the association studies have failed to
demonstrate a role for IL-12/Th1 pathway–specific genes such
as IL12A, IL12RB2, and IFNG. Thus, the genetic evidence
aligns more closely with a Th17 rather than Th1 immune
skewing in psoriasis.
There are a number of genes associated with psoriasis that
may function downstream of the IL-17 receptor signaling. Of
particular recent interest is TRAF3IP2 coding for the Act-1
protein (also known as TRAF3-interacting protein 2), an
intracellular protein that directly binds the IL-17 receptor
complex (Ellinghaus et al., 2010). Act-1 can initiate two
different signal transduction pathways in response to IL-17R
activation. NF-kB signaling events can be initiated through
interactions with TRAF6 (Schwandner et al., 2000). In the
TRAF6-independent pathway, Act-1 can bind to TRAF5 and
sequester the RNA binding factor SF2, leading to stabilization
of inflammatory mRNAs (Hartupee et al., 2007; Gaffen,
2011; Sun et al., 2011; Figure 1). The risk haplotypes have a
common defect in the ability of Act-1 to bind TRAF6
(Huffmeier et al., 2010) and thus presumably have decreased
IL-17R–dependent NF-kB signaling, although this was not
specifically demonstrated. This suggests the possibility that
the psoriasis risk may be driven by increased proinflamma-
tory activity through the Act1-TRAF5 mRNA stabilization
pathway. Additional candidate genes implicated in psoriasis
include other NF-kB pathway regulatory genes (REL, TNIP1,
TNFAIP3, and NFKBIA) and increased copy number of the
gene segment harboring the IL-17–regulated gene, DEFB4,
which encodes for human b-defensin 2 (Table 1).
The presence of both Th1 and Th17 subsets in psoriasis
may seem counterintuitive given that these two polarized
subsets have counter inhibitory effects on each other (Bettelli
et al., 2006). Under certain conditions, however, such as
those that exist in psoriatic lesions, Th1 cells promote
expansion of Th17 cells (Kryczek et al., 2008). In addition,
there appears to be considerable plasticity in this system;
Th17 cells have the ability to differentiate into IFN-g–
producing Th1 cells (Nistala et al., 2010; Hirota et al.,
2011) although not vice versa. CD8þ T cells are found in
increased numbers in the psoriatic epidermis, including
subsets producing IFN-g (Tc1), IL-17 (Tc17), and/or IL-22
(Tc22; Res et al., 2010). Similar to Th17 cells, Tc17 cells are
dependent on IL-23 for maintenance and expansion (Ciric
et al., 2009). The notable presence of Tc17 cells in the
epidermis, where IL-17 receptor is abundantly expressed on
keratinocytes, suggests a potential pathogenic role for this
subset of IL-17–producing cells (Figure 2).
Global gene expression studies have consistently demon-
strated the upregulation of the IL-17 pathway in psoriasis.
Several studies have used quantitative real-time PCR assays to
show increased expression of IL-17 ligands and the IL-23
subunits in lesional skin compared with both nonlesional and
normal skin (Zaba et al., 2007; Lowes et al., 2008; Harper
et al., 2009; Johansen et al., 2009). Microarray studies
demonstrate that many thousands of transcripts are differen-
tially regulated in the disease state (Yao et al., 2008;
Gudjonsson et al., 2010), and successful therapy is accom-
panied by rapid and nearly complete reversion of expression
of a wide range of genes (including cytokines, AMPs, and
IL-22
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IL-17A/F
CCL20
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Angiogenesis
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Figure 2. A model for the central role of IL-17 in psoriasis pathogenesis. This
model includes core inflammatory elements that establish a self-reinforcing
cycle, including T-helper 17 (Th17) skewing of naive T cells in the presence of
IL-23 leading to the local production of IL-17 ligands. Keratinocytes in turn
are stimulated by these IL-17 ligands, leading to an aberrant differentiation
program and elevated production of proinflammatory factors including
antimicrobial peptides (AMPs) and chemokines (including CCL20, which
attracts both Th17 cells and dendritic cells [DCs]). These keratinocyte-derived
factors in turn stimulate further recruitment of inflammatory cells, including
IL-17–producing cells, and establish a self-sustaining inflammatory feedback
loop. CXCLs, CXC ligands; Tc, T cytotoxic; TNF, tumor necrosis factor.
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downstream effector molecules) to near normal (nonlesional)
levels, suggesting that these alterations in gene expression are
necessary for therapeutic response (Zaba et al., 2009; Russell
et al., 2010, 2011). Again, elements upstream and down-
stream of IL-17 show higher expression, implicating the
pathway in psoriasis. Notably, among the genes that are
universally overexpressed across several studies are those for
IL-17A and IL-17F, IL-23, and a number of proinflammatory
genes regulated by IL-17A in keratinocytes, such as
b-defensin, neutrophil chemoattractants, and the chemokine
CCL20 (Nograles et al., 2008).
Consistent with the results described above is the
observation that IL-17 ligands (including both IL-17A and
IL-17C) and TNF-a amplify each other’s effects, both
additively and synergistically, and their combined activity
accounts for many of the key inflammatory pathways in
psoriasis (Chiricozzi et al., 2011). Some of this synergy may
be the result of the distinct mechanisms by which IL-17 and
TNF each regulate downstream gene expression. The TNF
receptor stimulates several pathways that activate gene
transcription, while major activities downstream of the IL-17
receptor include modulation of NF-kB signaling and stabili-
zation of mRNAs induced by TNF (Hartupee et al., 2007; Sun
et al., 2011). The synergistic interaction between IL-17 and
TNF, as well as the regulation of IL-17 by IL-23, is a potential
unifying theme in understanding the success of different
therapeutic agents in psoriasis, including the calcineurin
inhibitors, and antibodies targeting TNF, IL-12/23-p40,
IL-23p19, IL-17A, and IL-17 receptor A.
ROLE OF IL-17 INHIBITION IN THE CLINIC
Along with our understanding of disease pathophysiology,
therapeutic efficacy in psoriasis has also advanced tremen-
dously over the past 20 years. Clinical response to TNF
antagonism in psoriasis has been shown to correlate with the
rapid early reduction of IL-23 and IL-17A, followed by later
reductions in Th1-associated genes (Zaba et al., 2007).
Studies with IL-12/23p40 (Leonardi et al., 2008; Papp et al.,
2008) and IL-23p19 (Sofen et al., 2011) antagonists have also
demonstrated clinical efficacy and support the role of IL-12/
IL-23 and Th17 cells in the pathogenesis of psoriasis.
Although the key cytokines released from human Th17 cells
that drive psoriasis pathogenesis, including IL-22 and/or IL-
17, remain unclear, direct antagonism of the IL-17A ligand
(Genovese et al., 2010; Hueber et al., 2010, 2011) and the IL-
17 receptor with brodalumab (Russell et al., 2010, 2011;
Papp et al., 2012) have demonstrated striking results in early-
phase clinical trials in psoriasis.
Secukinumab (AIN457) is an anti–IL-17A ligand mAb that
has been assessed for the treatment of psoriasis, rheumatoid
arthritis, chronic noninfectious uveitis, and Crohn’s disease
(Hueber et al., 2010, 2011). A phase 1 study in 36 patients
with psoriasis showed that a single dose of secukinumab at
3mg kg1 significantly reduced disease severity (mean
psoriasis area and severity index [PASI] score) by 63% at
week 12 versus 9% for placebo (Hueber et al., 2010). Clinical
responses were associated with reductions in epidermal
hyperplasia, expression of IL-17Aþ and CD3þ cells from
immunostained micrographs, and gene expression of various
cytokines and chemokines (e.g., IL-17A, IL-21, IL-22, CCL20,
KRT16, and DEFB4; Hueber et al., 2010). Data from three
phase 2 studies showed 12-week PASI75 response rates of
81% in patients with psoriasis treated with subcutaneous
secukinumab 150mg (three or four doses) and 83% in
patients treated with intravenous secukinumab 10mgkg1
(three doses; Rich, 2011; Papp, 2011a, 2011b). LY2439821
(ixekinumab) is a mAb to IL-17A that is being investigated for
the treatment of psoriasis and rheumatoid arthritis (Genovese
et al., 2010). Recent data from a phase 2 study showed week
12 PASI75 response rates of 77%, 83%, and 82% following
administration of subcutaneous ixekinumab 25mg, 75mg,
and 150mg (weeks 0, 2, 4, 8, and 12), respectively, versus
7.7% for placebo (Leonardi et al., 2012). Up to 72% of
patients in the active-treatment groups achieved clear/almost
clear status according to Physician’s Global Assessment.
Brodalumab (AMG 827) is an IL-17 receptor A mAb that is
under investigation for a number of inflammatory conditions,
including psoriasis, psoriatic arthritis, and asthma. A phase 1
proof-of-concept study in patients with psoriasis demon-
strated significant improvements in clinical parameters: seven
of eight and five of eight patients achieved PASI75 by week 6
in the high (700mg intravenous) and moderate (350mg
subcutaneous) single-dose groups, respectively (Russell et al.,
2010, 2011). Improvements in histopathological parameters
included reductions in epidermal thickness, Ki-67 counts (an
index of proliferation-specific nuclear antigen; Gerdes et al.,
1983), keratin-16 gene expression, and infiltrating leukocyte
subsets (Russell et al., 2010, 2011). In a phase 2 dose-ranging
study, AMG 827 (70, 140, or 210mg at weeks 0, 1, and 2,
then every other week or 280mg monthly) produced dose-
dependent improvements in PASI and Physician Global
Assessment responses (Papp et al., 2012). Significant mean
PASI improvements at week 12 were 45%, 86%, 86%, and
76% in the AMG 827 70-, 140-, 210-, and 280-mg groups,
respectively, compared with 16% in the placebo group.
PASI75 responses were observed in 33%, 77%, 82%, and
67% of patients, respectively, in the AMG 827 groups and
0% in the placebo group. Similar results were observed for
other PASI measures and Physician’s Global Assessment, with
up to 85% of patients in the AMG 827 groups achieving
clear/almost clear status.
The significant clinical responses in patients with psoriasis
following blockade of either IL-17 receptor A (with brodalu-
mab) or its ligand IL-17A (with secukinumab and ixekinu-
mab) confirm the hypothesis that IL-17 signaling has a critical
role in this immune-mediated disease. Furthermore, the
complete reversal of regenerative epidermal hyperplasia
and high PASI responses seen with AMG 827 implies that
factors signaling through the IL-17 receptor A, including
IL-17A, IL-17C, and IL-17F, are central drivers of psoriasis
immunopathogenesis.
AN EMERGING MODEL FOR THE ROLE OF IL-17 IN
PSORIASIS PATHOGENESIS
This review has focused on the emerging role of IL-17 in the
pathogenesis of psoriasis, including preclinical results,
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genetic data, and both indirect and direct evidence from
clinical studies. These findings demonstrate the central
importance of this innate family of proinflammatory cyto-
kines in psoriasis. A model for the role of various factors in
psoriasis pathogenesis is presented in Figure 2. Notable
features in this model include a set of core inflammatory
elements that establish a self-reinforcing cycle, along with
ancillary proinflammatory elements that synergize with and
amplify the core elements. The core elements include: (a)
naive T-cell skewing into the Th17 lineage following
interaction with activated dendritic cells in the presence of
IL-23; (b) local Th17 production of IL-17A and IL-17F; and (c)
keratinocyte stimulation by IL-17 ligands leading to aberrant
differentiation and proliferation and the production of
proinflammatory AMPs, chemokines, and angiogenic factors,
which in turn stimulate further recruitment of inflammatory
cells, setting up a positive feedback loop. The chemokine
CCL20 is a notable keratinocyte-derived core component that
functions to recruit both inflammatory dendritic cells and
Th17 cells into active lesional skin. Additional ancillary
factors in this inflammatory network include cytokines (e.g.,
IL-22, which promotes keratinocyte alterations, and TNF,
which can synergize with IL-17 ligands to promote inflam-
mation); Th1 and Th22 cells, which amplify the core
response via the production of inflammatory factors; and
keratinocyte-derived angiogenic and chemoattractant
factors. The core and ancillary elements in this model
function together to establish an activated inflammatory
network, ultimately resulting in the formation of psoriasis
lesions.
Advances in genetics and immunology have enabled the
development of targeted therapeutics in psoriasis, a number
of which have shown impressive clinical efficacy. Clinical
and molecular data from these therapeutic successes have
provided additional opportunities to focus on and identify
inhibitors or central drivers of psoriasis pathogenesis, includ-
ing therapeutics targeting the IL-17 family. As our under-
standing of psoriasis pathogenesis increases, the parallel
evolution of increasingly selective therapies may provide
patients with an optimal balance between increased clinical
benefit and reduced risk for side effects. The early clinical
results from inhibition of IL-17 (ligand or receptor) have
established this cytokine as a core downstream element in
psoriasis, and ongoing late-phase studies will allow further
confirmation of these findings.
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